Pharma Operations

In: Business and Management

Submitted By ankitnigam
Words 268
Pages 2
The manufacturing process of pharmaceutical industry usually have products in the forms such as tablets, which is a complex multi-stage process under which the starting materials change their physical characteristics a number of times before the final dosage form is produced.
Tablets have been made by granulation, a process that imparts two primary requisites to formulate: compactibility and fluidity. Both wet granulation and dry granulation (slugging and roll compaction) are used. Regardless of weather tablets are made by direct compression or granulation, the first step, milling and mixing, is the same; subsequent step differ.
Numerous unit processes are involved in making tablets, including particle size reduction and sizing, blending, granulation, drying, compaction, and (frequently) coating. Various factors associated with these processes can seriously affect content uniformity, bioavailability, or stability.

Figure.20. Various Unit Operation Sequences In Tablet Manufacturing

Figure.21. Typical Manufacturing Process Of Tablet
Table.22. Typical Unit Operation Involved In Wet Granulation, Dry Granulation And Direct Compression(13) WET GRANULATION | DRY GRANULATION | DIRECT COMPRESSION | 1.
and mixing of drugs and excipients | 1.
and mixing of drugs and excipients | 1. Milling and mixing of drugs and excipients | 2.
of binder solution | 2.
into slugs or roll compaction | 2.
Compression of tablet | 3.
massing by addition of binder solution or granulating solvent | 3.
and screening of slugs and compacted powder | | 4.
of wet mass | 4.
with lubricant and disintegrant | | 5.
of the wet granules | 5.
of tablet | | 6.
of dry granules | | | 7.
with lubricant and disintegrant to produce “running…...

Similar Documents

Accounting for Pharma Co.’S Restructuring Program of Relocating a Manufacturing Operation Including Terminating Certain Employees Under Ifrss and Gaap.

...Pharma Co. Date: October 8, 2012 Prepared by: Lily Xu Reviewed by: Professor Dennis Goodman ISSUE: Accounting for Pharma Co.’s restructuring program of relocating a manufacturing operation including terminating certain employees under IFRSs and GAAP. BRIEF BACKGROUND Pharma Co. is a U.S. subsidiary of a U.K. entity that prepares its financial statements in accordance with (1) U. S GAAP for reporting to its U. S.-based lender and (2) IFRSs in reporting to its parent. Pharma. Co is in the process of restructuring a business line. As part of the restructuring, Pharma Co. is considering the relocation of a manufacturing operation from its present location to a new facility in a different geographic area. The relocation plan would include terminating certain employees. Pharma Co. has taken the following actions for the restructuring: 1. On December 15, 2010, Pharma. Co. issued a press release announcing its intentions to terminate its operating lease. The lease agreement stipulates that written notice is required for early termination. The lease termination fee is $1.3 million. The company plans to vacate the leased plant and sign the lease termination agreement on January 31, 2011. 2. On December 27, 2010, Pharma Co. management communicated the one-time termination plan to its employees. The plan involves a reduction of approximately 120 employees. The workforce reduction is expected to be complete by January 31, 2011, and is expected to cost approximately $3......

Words: 2559 - Pages: 11

Pharma want to focus their health on something that never existed earlier and getting things easier is their motto. 3) Licensing from smaller companies and utilizing vertical integration, As the smaller companies lack in sales, marketing and development, the research could be outsourced to smaller companies by large players in the pharmaceutical industry. This is the easiest way for many companies to operate as the drugs could be licensed and then be marketed by larger firms. Recommendation: I would strongly suggest the third, to license from smaller companies, this allows larger companies to do what they can do best, sell the drug and the smaller companies to focus on just research rather than having to complicate their business operations by allocations of funds otherwise....

Words: 380 - Pages: 2


...Respected Sir/Madam, I xxxx completed Bachelors in xyz College of xyz affiliated to University, Mumbai with 50% Following this, I was involved in research and has been working as an Analyst for Plant pharmaceuticals in Quality Control Department of Alapati Pharma company. I was Kindled with an ambition of higher education that would give a desired push to my career. With a strong will to pursue my further studies in Canada, I prepared for the IELTS examination and scored 6.5 bands. I am prepared to further deepen and refine my expertise through Biotechnology Course which has led me to take admission in one of the top Colleges, Centennial College, Canada. I was brought up in a well educated family and this helped me to maintain a consistent and excellent academic record; I secured Distinction marks in SSC and Intermediate. During my Bachelors, I submitted many research papers in worldwide and India wide seminars like IPC, IPA, National seminars where 12 of my Research papers were published in Medical and Pharmacy Journals. I was also awarded a "Gold medal" for a Seminar conducted by Indian Pharmaceutical Congress which provided me a wonderful platform to meet the top heads of Pharmaceutical Industry in the country. I Started my career as an Asst. Manufacturing Chemist in Triomed Formulations India(Pvt) Ltd as soon as i was graduated. Then i opted for a Subject Knowledge Enhancement Course......

Words: 741 - Pages: 3


........................ 35 MERGER AND ACQUISITION (M&A) ACTIVITIES .................................. 36 MARKET OUTLOOK AND RECOMMENDATIONS ...................................... 38 COUNTRY PROFILES ......................................................................................... 41 COMPANY PROFILES ........................................................................................ 48 GCC Pharmaceutical Sector | March 31, 2013 Page | 3 “The pharma sector in Qatar is poised for growth over the next few years in line with the growth trend in GCC, which is the wider market segment. A major driver to this will be the projected growth in the economy. On the regulatory side, the recent legislation proposed by the Supreme Health Council towards deregulation of pharmaceutical imports to encourage free market competition is a step in the right direction. The industry is also looking forward to the proposed national health insurance program, as this is perceived to be a catalyst to growth of the pharma industry in Qatar.” Sheikh Faisal Bin Qassim Al Thani Chairman Aamal Company (Ebn Sina Pharmacy) “The GCC pharmaceutical sector has been growing steadily along with the general uptrend within the region. The pharmaceutical sector is highly regulated in nature and hence comes with its own limitations with regards to registration and entry into new markets. However, the recent trend of increased use of generics and the growth in medical insurance penetration will...

Words: 27542 - Pages: 111

Pharma Industry

... | |EUR / USD |1.2438 | |GBP / USD |1.8333 | |USD / JPY |108.1508 | |USD / CHF |1.2426 | |Source: calculated using Federal Reserve daily data | Industry Trends Here we examine structural changes causing significant transformations, major factors leading to strong future sales growth, and point out the industry’s strong reliance on research and development. Structural changes The pharmaceutical industry is currently undergoing a period of very significant transformation. The majority of “Big Pharma” companies generate high returns, thus providing them with excess cash for further rapid growth – whether organic, or through mergers and acquisitions. Although size of the company on its own does not guarantee success, it gives a significant advantage, especially in pharmaceutical industry. Besides economies of scale in manufacturing, clinical trials and marketing, bigger companies can allow investments in more research and development (R&D) projects that diversify their future drugs portfolio and make them much more stable in the long term. As the result, top-companies in the industry were active participants of mergers and acquisitions (M&A), new joint ventures and spin-offs of non-core businesses. The largest acquisitions in the......

Words: 10094 - Pages: 41

Pharma, Co

...10-3 Restructuring Costs Pharma Co. is a U.S. subsidiary of a U.K. entity that prepares its financial statements in accordance with (1) U.S. GAAP for reporting to its U.S.-based lender and (2) IFRSs in reporting to its parent. Pharma Co. is in the process of restructuring a business line. As part of the restructuring, Pharma Co. is considering the relocation of a manufacturing operation from its present location to a new facility in a different geographic area. The relocation plan would include terminating certain employees. IAS 37 includes guidance for accounting for restructuring costs in accordance with IFRSs. Paragraph 10 of IAS 37 defines restructuring as follows: [A] programme that is planned and controlled by management, and materially changes either: a. the scope of a business undertaken by an entity; or b. the manner in which that business is conducted. Under IFRSs, emphasis is placed on the recognition of the costs of the exit plan as a whole, whereas under ASC 420-10 in U.S. GAAP, each type of cost should be examined individually to determine when it should be accrued. As a result, there may be differences in timing of recognition of restructuring costs under IFRSs and U.S. GAAP. Pharma Co. has taken the following actions: 1. On December 15, 2010, Pharma Co. issued a press release announcing its intentions to terminate the lease of the old facility. The press release is included as Appendix A. Assume the terms of the lease are such that Pharma Co. accounts for the......

Words: 908 - Pages: 4


...RESEARCH PROJECT ON “TRAINING AND DEVELOPMENT IN PHARMASUITICAL INDUSTRY WITH SPECIAL REFERENCE OF MANKIND PHARMA LTD” SUBMITTED IN PARTIAL FULFILLMENT OF DEGREE OF BACHELOR OF BUSINESS ADMINISTRATION SESSION (2011-2014) SUBMITTED TO: SUBMITTED BY: XYZ XYZ BBA III University Roll No. SUBMITTED TO ACKNOWLEGDEMENT “Gratitude is the hardest of emotions to express and one often does not find adequate words to convey what one feels and trying to express it” The present project file is an amalgamated of various thoughts and experiences .The successful completion of this project report would have not been possible without the help and guidance of number of people and specially to my project guide .I take this opportunity to thank all those who have directly and indirectly inspired, directed and helped me towards successful completion of this project report. I am also immensely indebted to my project guide, MS. Divya Vaid Lecturer, ICL, for his......

Words: 8569 - Pages: 35

Pharma 2020 Pharma 2020: Supplying the future Which path will you take? Pharmaceuticals and Life Sciences Previous publications in this series include: Pharmaceuticals Pharma 2020: The vision Which path will you take?* Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike. Pharmaceuticals and Life Sciences Pharma 2020: Challenging business models Which path will you take? Fourth in the Pharma 2020 series and published in April 2009, this report highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry. *connectedthinking Pharma 2020: The vision  # Pharmaceuticals and Life Sciences Pharma 2020: Virtual R&D Which path will you take? This report, published in June 2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and......

Words: 13197 - Pages: 53

Pharma Industry

...INDIAN PHARMACEUTICAL INDUSTRY – AN OVERVIEW 1. Overview The Indian Pharma industry is one of the fastest growing sectors with approximately 20,000 manufacturing units. The industry that is highly price sensitive ranks thirteenth in the global pharmaceutical market in value terms and fourth in volume terms. The country has tremendous export potential in the areas like custom synthesis, R&D, clinical trials, and Bioinformatics. The industry produces 60,000 finished medicines and roughly 400 bulk drugs, which are used in formulations with about 20% of the manufacturers in the bulk drugs segment. India has approximately 1% share of global pharma industry, which is worth US$406 billion. This implies that there is a huge market waiting to be unfolded. The figure below explains the evolution of Indian pharmaceutical industry: Figure 1: Progress Of Indian Pharmaceutical Industry Source: (Article by Dr. Laxman Prasad) 2. Industry Structure and Size 2.1 Industry Structure The Indian Pharma industry is highly fragmented and can broadly be classified in to two categories: organized and unorganized sector. Figure 2: Revenues of Organised vs. Unorganised Sector Source: Secondary Research The organized sector contributes about 70% of the total revenues and consists of 260 units in both manufacturing as well as formulation segment. This sector can further be divided into Indian and multinational companies. The unorganized sector is...

Words: 1530 - Pages: 7


...production in the developing world, in turn lowering production costs allowing for cheaper prices to be offered. As Kyle (2007) states, price controls can affect a company’s decision to launch a specific drug into a country, this view is also supported by Lanjouw (2005). Recommendations It is simplistic to say that the pharmaceutical companies should just meet the expectations of the world and eliminate disease. There is always an argument for companies to do more but there comes the stage where you are just putting a plaster on an infected laceration: the medicines alone will not eradicate disease in the developing world. After considering the current practices and research, it becomes apparent that the multi-factorial approach in operation is assisting the control of malaria but is failing to control. With the long term plans set out by these agencies, it does not seem that any country will gain control of the spread of disease until basic living conditions are improved and medical care are available through out. Infection rates appear to be perpetual, by investing aid into infrastructure, health provision and education by bypassing alleged government corruption this growth will be hampered. With the introduction of larvicidal fish and irrigation of surplus water collections and marshes drastically reduce the habitats in which the mosquito breeds and will by nature reduce mosquito populations, potentially attacking the issue at the first opportunity. This will......

Words: 2477 - Pages: 10

Beximco Pharma

... Executive Summary After growing at a robust twenty plus percentage in 2010 and 2011, Bangladesh Pharmaceutical Industry experienced a slower growth in 2012. The market grew by 11.9% in value terms to reach at Tk. 94 billion (IMS: Q4 2012 report). Despite a slower growth in the market, Beximco Pharma managed to achieve desired growth and successfully improve its market share. The country continued to maintain 6% plus GDP growth rate in 2012 as well. The alarming depreciation of Taka against US Dollar that continued throughout 2011 till January 2012 has finally been restrained. Thanks to higher inward remittances, lower payment for import settlements, and moderate growth in export. The local currency appreciated by around 2.5% against US Dollar in 2012. This was somewhat a relief to the predicted risk of significant reduction of gross margin that started brewing in 2011 in the wake of deteriorating value of local currency against US Dollar, high rate of domestic inflation and increase in the interest rates. The liquidity shortage that prevailed throughout 2011 also eased up to some extent in 2012. However, the political crisis that started by end of 2012 centering the upcoming election poses some degree of uncertainty in the overall economic environment of the country and is seen as an impediment to the growth of business. The first quarter of 2013 has already been affected for such instability in the political environment and continues to remain as a risk factor. ...

Words: 5929 - Pages: 24

Indian Pharma

...Pharmabiz :: Vision of India as pharma power house in 2020 Page 1 of 3 Search Here Search Home Editorial Services Interview Q&A Chronicle Specials ePharmail Archives Join Pharma | Login Home > Chronicle Specials News + Font Resize - Vision of India as pharma power house in 2020 Nandita Vijay, Bengaluru Thursday, December 15, 2011, 08:00 Hrs [IST] The Indian pharma industry has gained significant global presence in the last few years and has been competing with other major countries on equal terms. Its remarkable growth can be attributed to its ability to rapidly access and adopt new technologies and also to its success in evolving an effective mechanism to strengthen research and development. The industry's advanced manufacturing facilities have earned laurels from global regulatory authorities. As a result, the world today turns to the Indian pharma industry not only for high-quality and low-cost generic drugs, but also for in-licensing and out -licensing of drugs. The robust Indian pharma industry today produces a range of formulations, has the expertise for active pharmaceutical ingredients (APIs) and sees significant opportunities for value-creation. Hence, the theme of the 63rd edition of IPC, ‘Pharma Vision 2020: India: The Pharma Power house’, encapsulates the present stature of the Indian pharma industry. India, the pharma power house India ranks third in terms of manufacturing pharma products by volume and 14th in value......

Words: 2709 - Pages: 11

Pharma, Co

...Solution for the Case 10-3 - Restructuring Cost Pharma Co. should account for the restructuring program in different ways for the U.K parent and to U.S.-based lender. A. With respect to IFRS, company should use IAS 19 and 37. According to the IAS 19, paragraphs 133 and 134, entity should recognize termination benefits when company terminates the employment of employees before normal retirement date and company has detailed formal plan for termination. This plan should include the location, function and number of employees whose services are to be terminated. The entire $3 million should be recognized as termination benefits according IAS 19, paragraph 135. After Inter-Office Memorandum from December 27, 2010 (appendix B) informing employess of one-time nonvoluntary termination plan, Pharma Co. should recognize a liability of $3 million for the termination benefits on its financial statements from December 31, 2010. Similar situation takes place with the respect of the cost of early lease termination. According to the IAS 37 paragraphs 5(c) and 14, Pharma Co. must apply this standard to operating lease termination case. Paragraphs 72-75 state clearely, Pharma CO should recognize entire $1.3 million announced in the press release from December 15, 2010, as the liability on its December 31, 2010 Balance Sheet. The cost of $1 million related to dismantlement of the existing manufacturing operation should be also included as liability on the December 1, 2010...

Words: 607 - Pages: 3

Pharma Analyse

...Analyse sectorielle Secteur de la « Santé / Pharma » 16 Avril 2009 Liminaires • Ce document a pour objet de dresser une analyse prospective de la filière « Santé / Pharma » – ses grands enjeux, ses forces en présence, ses mutations en cours – et de donner à voir des pistes de réflexions / de solutions, en particulier pour les laboratoires pharmaceutiques. • Il est organisé en trois principaux chapitres : • Premier chapitre : diagnostic flash du secteur restitué sous la forme d’une représentation de la • • filière et de ses mutations majeures. Deuxième chapitre : pistes de réflexion / de solution à engager à court ou moyen terme pour répondre aux changements (outre celles d’ores et déjà engagées par les leaders de la filière). Troisième chapitre : analyse détaillée de la filière. • Les abréviations / sigles techniques spécifiques au secteur sont explicités dans un glossaire chapitre 4. 2008 Copyright emoveo sarl. Tous droits réservés 2 Sommaire • 1- Représentation de la filière Santé / Pharma et de ses mutations majeures • Contexte et enjeux majeurs • Tendances de fond et ruptures • Chaîne de valeur et changements induits • Emergence de nouveaux acteurs • 2 - Pistes de réflexions et de solutions • 3 - Analyse détaillée de la filière • Analyse de marché et analyse de l’environnement • Extraits du rapport d’étude « Pharma 2020 : The vision – Which path will you take ? » • Zoom sur les outils CRM Pharma • Fiches d’identité des 15 premiers......

Words: 8260 - Pages: 34

Pharma Aspiring giants How small pharmas can drive to $1 billion — and beyond PwC’s PRTM Management Consulting Aspiring giants Executive summary Amid the volatile blend of opportunity and challenge that characterizes the global pharmaceutical industry, only a few small companies have managed to catapult their revenue over the $1 billion mark over the past two decades. Whether they chose to expand their therapeutic area focus and product portfolios, enter new geographies, or grow their core business, these aspiring giants pursued three distinct strategies to jump-start growth:  Leveraged core product and technology capabilities to launch differentiated products  Used mergers and acquisitions to gain new products and/or expand geographic presence  Built a strong, stable leadership team armed with a compelling vision and relentless drive The experiences of these winning companies offer lessons for today’s smaller pharma companies harboring the ambition to reach the $1 billion revenue mark. To achieve this milestone, these companies will need to excel in three areas: expanding a core area of expertise to deliver niche and valueadded products, adopting an acquisition and partnering mindset to expand product offerings and geographic presence, and attracting and retaining talented leaders. Focusing on these fronts can help position a pharma company to become a growth leader—rather than merely a follower—in......

Words: 4167 - Pages: 17

Operacja Dunaj (2009) | Derren Brown: The Push | 510 Telecharger War Dogs Gratuit War Dogs (previously known as Arms and the Dudes) is an upcoming 2016 American biographical crime war comedy film directed by Todd...